Background and aims: Drug induced autoimmune hepatitis (DIAIH) remains poorly
Introduction
Autoimmune hepatitis (AIH) is a chronic disorder of unknown aetiology characterised by presence of autoantibodies, hypergammaglobulinaemia, and interface hepatitis with about 85% showing an excellent response to immunosuppression (1, 2) .
A number of factors predict outcome in AIH including presence of cirrhosis, normal transaminases during follow up and ethnicity (3) (4) (5) (6) . Despite increasing interest in drug induced AIH (DIAIH), this remains an uncharacterised cohort with lack of consensus regarding diagnostic criteria, need for long-term immunosuppression and outcomes (7) (8) (9) (10) (11) . This is mainly due to difficulty in differentiating between drug induced liver injury (DILI), immune DILI, DIAIH and coincidental drug use. Another contributing factor is that patients presenting with DILI can eventually develop AIH after varying periods of latency (11) (12) (13) .
The natural history of DIAIH is therefore controversial with some suggesting a benign course (absence of hepatic fibrosis and no relapse after immunosuppression discontinuation) (8) , with others reporting advanced hepatic fibrosis and failure to maintain remission after discontinuation of prednisolone/azathioprine (7) .
The aim of this study therefore was to assess natural history and outcomes in patients with DIAIH and to further stratify natural history of DIAIH depending on the nature of the culprit drug.
Patients and methods
This retrospective cohort study included all patients with AIH being followed up between Jan 2005 and Oct 2013 at a teaching hospital in southeast England, with last follow up recorded as of June 2014. Patients were identified via the electronic histopathology and clinic letters databases.
Autoimmune hepatitis was defined by criteria established by the International Autoimmune
Hepatitis Group (14) .
Study definitions
• DIAIH:
-Normal liver tests (if available) prior to drug initiation -No pre existing liver disease -Definite temporal association between drug initiation and subsequent diagnosis of AIH -Other causes for liver disease diligently excluded -Probable or definite by revised AIH criteria (14) -Roussel Uclaf Causality Assessment Method (RUCAM) score of highly probable (>8) or probable (6) (7) (8) (15) • Acute presentation: Bilirubin ≥ 5xULN and or ALT > 1000 IU/L.
• Liver failure: Presence of any degree of hepatic encephalopathy and or international normalised ration (INR) ≥ 2
• Remission: Normal ALT/resolution of symptoms, and if available normal IgG and histology
• Relapse: ALT ≥ 2ULN with/without symptoms on treatment discontinuation
• Poor outcome: Failure to achieve remission, liver failure (either at initial presentation or follow up), development of cirrhosis during follow up, development of cirrhosis complications, need for liver transplantation (LT) and/or liver related mortality (LRM).
Cirrhosis related complications were defined as any one or more of the following: ascites/spontaneous bacterial peritonitis, high risk varices/variceal bleed, hepatocellular cancer and hepatic encephalopathy
The exclusion criteria were
• Overlap syndrome including biliary pathology such as primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune cholangitis.
• Co existing liver disease due to alcohol, viral hepatitis, non-alcoholic fatty liver disease
• Incomplete medical records
A detailed review of the medical records (medical notes and electronic pathology and radiology database) was performed for those considered to have AIH and for each patient the following data was collected anonymously: demographics, autoantibodies (ANA, SMA, AMA, LKM), hepatitis serology, alcohol history, autoimmune hepatitis score [assessed by revised International Autoimmune Hepatitis Club diagnostic criteria (14) , dose and duration of culprit drug (in cases of DIAIH), liver tests at onset, during remission and at last follow up and presence of additional autoimmune conditions. The liver biopsy report for each individual was reviewed and the following data collected: fibrosis stage (Ishak), presence of portal and lobular inflammation, and interface hepatitis, (all classified semi quantitatively as mild, moderate or severe), portal and lobular plasma cells, lymphocytes, neutrophils and eosinophils, collapse, necrosis, cholestasis and rosettes (all as yes/no).
In those individuals where the initial liver biopsy report was incomplete or unavailable, the biopsies were re reviewed by a dedicated local pathologist (MH) (see acknowledgement)
Statistical analysis
Data are presented as mean standard deviation, median (interquartile range) or number (%) and all reported p values are two-tailed. The Mann-Whitney U and Student's t tests were used to compare non-parametric and parametric continuous variables respectively and categorical data were compared using the  2 test/Fisher exact test. Kaplan-Meier (KM) curves were generated to assess probability of poor outcome in those with DIAIH and AIH. Statistical analyses were undertaken using SPSS Version 22 (Armonk, NY, IBM Corp).
This study was classified as service evaluation by our Internal Institutional Ethical Sponsorship Group and hence they determined that individual patient consent and formal National Research Ethics Approval were unnecessary.
Results
During the study period 109 potential patients were identified. Of these 27 were excluded as:
presence of overlap syndrome/biliary (n=17), coexisting liver disease (n=3)(non-alcoholic fatty liver disease n=2, chronic hepatitis C, n=1), drug induced liver injury (n=2), positive hepatitis E serology (n=1), and medical records not available (n=4 and 70/80 (78.7%) patients respectively. In the eight with no liver biopsy report available, the initial diagnosis had been made at an outside hospital of whom in four (50%) this was at a regional transplant centre. Sixty of the 72 biopsies (83.3%) biopsies had either been reviewed by a dedicated local hisopathologist (MH) and or by two dedicated hisptopathologists (BP and AK) at the regional transplant centre (see acknowledgement). This included ten biopsies that were re reviewed by the local dedicated histopathologist (MH) as the original report was incomplete.
Data in patients with DIAIH and AIH.
Of the 82 patients identified with AIH, 11 (13.4%) were considered to have DIAIH (table 2) .
RUCAM scores were probable for all 11 cases ranging between 6-8 (table 2) . The implicated drugs were nitrofurantoin (n=4), statins (n=4), herbal remedies (n=2), and diclofenac (n=1).
The herbal remedies included Echinacea (used for the common cold) and valerian (used for insomnia). All but two (18.1%) patients with DIAIH were female. In eight (72.7%), baseline liver tests were normal prior to initiation of the offending drug, these being unavailable in three patients. Hepatitis E serology was available in six (all negative). Seventy percent with DIAIH had elevated IgG. The mean duration of drug use prior to diagnosis of DIAIH was 23.1 +15.6 mths. Eosinophilia was not reported in any of the 11 patients though two (patient no 4 and 11) developed a transient rash after use of concomitant drugs (salazopyrin and unknown antibiotic). However both already had symptoms/abnormal liver tests at time of initiation of the concomitant drugs. Table 3 shows data in those with and DIAIH and AIH. The former were more likely to be > 60 years at presentation (p=0.048), score as probable AIH on revised criteria (p=0.012), and take longer time to relapse after discontinuation of immunosuppression (p=0.038). There were no significant differences as regards gender, liver tests at presentation, acute presentation, presence of other autoimmune conditions, symptoms, fibrosis stage and cirrhosis at onset, presence of portal/lobular inflammation, interface hepatitis, plasma cells, lymphocytes, eosinophils, neutrophils, collapse, cholestasis, rosettes and treatment schedules (p>0.05) (table 3) . In 17/76 (22.4%) treated patients (two with DIAIH) additional drugs were used: 6-mercaptopurine (n=11, due to azathioprine intolerance); mycophenolate(n= 5, in two azathioprine intolerance and in three suboptimal response to azathioprine); and cyclosporine (n=1, suboptimal response to azathioprine).
In the AIH and DIAIH groups, median dose of prednisolone at onset was 30mg (5-60) and 30 mg (10-40), (p=0.133) and 7.00mg (2.50 -40) and 15.0mg (5 -40) at last follow-up respectively (p=0.031). Similarly, in the AIH and DIAIH groups, the median dose of azathioprine at onset was 50mg (50 -150) and 50mg (50 -100) (p=0.616) and 50mg (50 -200) and 50mg (50 -100) at last follow-up respectively (p=0.572).
Forty-two (51.2%) had other extra hepatic autoimmune disorders, though the prevalence was no different in those with DIAIH and AIH (table 3) . These included thyroid disease(n=22), rheumatological conditions (n=13), dermatological disorders(n=3), autoimmune haemolytic anaemia n=2, gastrointestinal (ulcerative colitis/celiac disease, n=3), vasculitis (ChurgStrauss/temporal arteritis, n=2) and extrinsic allergic alveolitis n=1. Four (9.52%) had more than one extra hepatic autoimmune condition. Of the five patients with DIAIH and additional autoimmune conditions three had thyroid disease.
Patients with nitrofurantion and non-nitrofurantoin DIAIH
Comparing those with (n=4) and without nitrofurantoin (n=7) DIAIH, the former were older and had lower ALT but higher fibrosis stage at presentation. The duration between drug initiation and detection of abnormal liver tests and duration between detection of abnormal liver tests and specialist review was longer in those with nitrofurantoin DIAIH. In all four cases with nitrofurantoin DIAIH, the drug was only discontinued after specialist review. This was in contrast to the non-nitrofurantoin group where in 74.1% (statins n=4 and diclofenac n=1) the drugs were discontinued by primary care physicians upon receipt of abnormal liver tests (table 5) . Despite shorter duration of immunosuppression prior to discontinuation none of the patients with nitrofurantoin DIAIH relapsed compared to all in the non-nitrofurantoin group (table 5) .
Outcomes
Overall 28 (34.1%) patients had a poor outcome (table 3 and 4) . This included six (7.3%)
with liver failure at onset of whom two also had cirrhosis, six (7.3%) developing cirrhosis during follow up (confirmed histologically in five and radiologically in one), fifteen (18.3%) developing cirrhosis related complications (ascites n=9, hepatic encephalopathy, n= 3, variceal bleeding/high risk varices, n= 6), five (6.5%) failing to achieve remission and two (2.4%) undergoing LT (some had more than one event). Of those with cirrhosis related complications, 12 developed them at presentation and the remaining three during follow up.
There were seven deaths (8.5%), one in DIAIH group, (non-LRM) and six in AIH group of which five (83.3%) were liver related. KM analysis showed that probability of a poor outcome was no different in those with DIAIH and AIH (log rank test 0.339) (fig 1) .
Discussion
In this retrospective cohort study we observed that approximately 15% of patients with AIH had DIAIH, the implicated drugs in three fourths being either nitrofurantoin or statins with herbal medication accounting for ~ 20% of the cases. The diagnosis of DIAIH was robustly made with all patients scoring as probable on the RUCAM scale. The natural history was similar in DIAIH and AIH especially as regards clinical presentation, presence of hepatic fibrosis, prevalence of cirrhosis and poor outcomes, and relapse rates. However, those with DIAIH were older (75% being above the age of 60 yrs), with a propensity for late relapse.
This was despite those with DIAIH having a higher dose of prednisolone at last follow up.
Finally, compared to the non-nitrofurantoin group, those with nitrofurantoin related DIAIH had more advanced fibrosis at presentation but lower risk of relapse on immunosuppression discontinuation. Increasing age is an established risk factor for DILI as also confirmed by
Bjornsson et al's recent population based study, where a two fold increase in crude annual incidence of DILI (19.1-39.9 /100,000) was observed in those < 25 yrs vs. > 70 yrs (16) .
Drug dosage also predisposes to DILI and in the aforementioned study, 88% with DILI received daily doses > 50 mgs (16) (30) have also reported presence of cirrhosis in DIAIH. Finally, in two recent reviews that included more than 100 cases of nitrofurantoin related DILI cirrhosis was not infrequently observed (18, 19) . These data suggest that advanced hepatic fibrosis can be observed in DIAIH and should not negate against its diagnosis.
Another factor stated to differentiate DIAIH and AIH is lack of relapse upon discontinuation of immunosuppression in the former (8) . Our relapse rates, though lower in DIAIH (60% vs. Stains and nitrofurantoin can cause both hepatocellular and cholestatic DILI as will as DIAIH (17) (18) (19) (20) (21) (22) . In a recent publication by the Drug Induced Liver Injury Network (DILIN), of the 22 patients identified with statin induced DILI, 6 (27.2%) were considered to have DIAIH (20) .
They were older than those with hepatocellular DILI (62 +10.3) vs. 53 +9.8) with half requiring immunosuppression and documented relapse in at least one patient. About 50% had been on a statin for longer than 12 months, consistent with our data (duration of statin use 9-36 months). In two reviews on nitrofurantoin DILI (19, 20) , 50% were above the age of 60 yrs, and 54% had taken the drug for two years or longer with six deaths and one patient undergoing LT. Bjornnson et al's recent study observed DILI in 1:1369 patients using nitoufurantoin, confirming that this drug is a rare yet serious cause of hepatotoxicity (16) .
We observed distinct differences between those with nitrofurantoin and non-nitrofurnatoin DIAIH. The former had longer duration of drug use prior to detection of abnormal liver tests and on going drug use despite abnormal liver tests, factors associated with more severe DILI (31) . This might be another explanation for the high prevalence of cirrhosis (50%) in this cohort. Interestingly all relapses occurred in the non-nitrofurantoin group though at present we are unable to offer an explanation for this.
Our 20% prevalence of DIAIH due to herbal remedies is consistent with recent DILIN data where herbal and dietary supplements accounted for 15.5% of the DILI cases, the prevalence however significantly increasing from 7% to 20% during the study period (2004-2013) (32).
Valerian is a common herbal medication that is used to treat insomnia and a recent US survey showed about 5.6% of adults having used it in the past year (33) . In 1989 MacGregor et al first reported valerian associated hepatotoxicity in a case series of 4 patients (of whom one had advanced fibrosis) (25), this being followed by another case report (26) . There have been warnings to avoid valerian in individuals with liver disease (34) . There are two prior case reports of Echinacea associated hepatotoxicity including one with positive autoantibodies (27, 28) . This study additionally highlights lack of awareness amongst healthcare professionals about the hepatotoxic potential of nitrofurantoin and herbal remedies as despite detection of abnormal liver tests both drugs were discontinued only after specialist review.
Though prevalence of poor outcome was lower in those with DIAIH (18.2 vs. 36.6%), this was not statistically different, as was also supported by the KM analysis. However it is noteworthy that none with DIAIH failed to achieve remission, develop fibrosis progression, needed a LT and or had a liver related mortality.
In conclusion the natural history of DIAIH appears to be similar to AIH especially as regards presence of advanced fibrosis at presentation and inability to maintain remission on immunosuppression withdrawal, especially in the non-nitrofurantoin group. These data suggest that at least some patients with DIAIH mandate long-term follow up. Nonetheless, this needs corroboration by larger prospective studies. 
